Compare QSI & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QSI | MXCT |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 136.2M |
| IPO Year | 2020 | 2021 |
| Metric | QSI | MXCT |
|---|---|---|
| Price | $1.38 | $1.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.30 | ★ $4.11 |
| AVG Volume (30 Days) | ★ 9.3M | 1.2M |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,436,000.00 | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $406.32 | $15.53 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $0.64 |
| 52 Week High | $2.42 | $1.81 |
| Indicator | QSI | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 63.11 |
| Support Level | $0.81 | $1.15 |
| Resistance Level | $1.66 | $1.54 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 59.23 | 75.59 |
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.